Company Overview - Oculis is a Swiss-based biopharma company focused on improving eye care and saving patients' vision, with operations in the US and Iceland [2] - The company has developed a differentiated pipeline of drug candidates for conditions such as diabetic macular edema (DME) and acute optic neuritis (AON) [2] Pipeline and Drug Candidates - Oculis has several late-stage clinical studies, including OCS-01, a potential treatment for DME, which affects over 37 million people globally, projected to rise to 53 million by 2040 [1][2] - OCS-01 is the first topical eye drop for DME, with two fully enrolled Phase 3 trials (DIAMOND) involving over 800 patients, and topline data expected in 2Q26 [7][10] - The company plans to submit a New Drug Application (NDA) to the FDA in 2H26, with the DME market estimated at $5 billion globally [7][10] - Oculis is also developing privosegtor (OCS-05) for AON and NAION, with several clinical trials underway, including positive results from Phase 2 trials [8][11] Financial Position - As of the end of Q3, Oculis had $182.2 million in cash and liquid assets, which increased to $300 million following a capital raise campaign in October [9] Analyst Insights - Analysts view Oculis as offering a diversified ophthalmology pipeline with high unmet needs, particularly for DME with OCS-01 showing promising efficacy and safety [10] - The stock has received a Strong Buy consensus rating, with a price target of $38 indicating an 81% upside potential, while the current stock price is $20.97 [11]

Core Viewpoint - Oculis Holding AG has announced the pricing of an offering of 5,432,098 ordinary shares at $20.25 per share, aiming to raise a total of $110 million before expenses, to support the development of its neuroprotective clinical candidate, Privosegtor, and for general corporate purposes [1][2]. Group 1: Offering Details - The financing consists of an underwritten offering of 4,691,358 ordinary shares and a registered direct offering of 740,740 ordinary shares, with the total expected to close around November 3, 2025 [3]. - Of the shares being offered, 2,635,801 are new shares issued from the Company's existing capital band, while 3,500,000 are treasury shares [3]. - The issuance of new shares will increase the total number of registered shares authorized by the Company to 57,169,475 [3]. Group 2: Use of Proceeds - The net proceeds from the financing will be utilized to advance the development of Privosegtor for treating acute optic neuritis (AON) and non-arteritic anterior ischemic optic neuropathy (NAION), along with working capital and general corporate purposes [2]. Group 3: Management and Advisors - J.P. Morgan, Leerink Partners, and Pareto Securities are acting as joint bookrunning managers for the underwritten offering, while Van Lanschot Kempen is the manager and Arctica Finance serves as a financial advisor [4]. Group 4: Company Overview - Oculis is a global biopharmaceutical company focused on innovations in neuro-ophthalmic conditions, with a late-stage clinical pipeline that includes three core product candidates: Privosegtor, OCS-01, and Licaminlimab [6]. - The company is headquartered in Switzerland and operates in the U.S. and Iceland, led by an experienced management team supported by international healthcare investors [6].